Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Nov 29;65(12):1977-1983.
doi: 10.1093/cid/cix724.

Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control Evaluation

Tami H Skoff  1 , Amy E Blain  1 , James Watt  2 , Karen Scherzinger  3 , Melissa McMahon  4 , Shelley M Zansky  5 , Kathy Kudish  6 , Paul R Cieslak  7 , Melissa Lewis  1 , Nong Shang  1 , Stacey W Martin  1
Affiliations

Impact of the US Maternal Tetanus, Diphtheria, and Acellular Pertussis Vaccination Program on Preventing Pertussis in Infants <2 Months of Age: A Case-Control Evaluation

Tami H Skoff et al. Clin Infect Dis. .

Abstract

Background: Infants aged <1 year are at highest risk for pertussis-related morbidity and mortality. In 2012, Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccine was recommended for women during each pregnancy to protect infants in the first months of life; data on effectiveness of this strategy are currently limited.

Methods: We conducted a case-control evaluation among pertussis cases <2 months old with cough onset between 1 January 2011 and 31 December 2014 from 6 US Emerging Infection Program Network states. Controls were hospital-matched and selected by birth certificate. Mothers were interviewed to collect information on demographics, household characteristics, and healthcare providers. Provider-verified immunization history was obtained on mothers and infants. Mothers were considered vaccinated during pregnancy if Tdap was received ≥14 days before delivery; trimester was calculated using Tdap date, infant's date of birth, and gestational age. Odds ratios were calculated using multivariable conditional logistic regression; vaccine effectiveness (VE) was estimated as (1 - odds ratio) × 100%.

Results: A total of 240 cases and 535 controls were included; 17 (7.1%) case mothers and 90 (16.8%) control mothers received Tdap during the third trimester of pregnancy. The multivariable VE estimate for Tdap administered during the third trimester of pregnancy was 77.7% (95% confidence interval [CI], 48.3%-90.4%); VE increased to 90.5% (95% CI, 65.2%-97.4%) against hospitalized cases.

Conclusions: Vaccination during pregnancy is an effective way to protect infants during the early months of life. With a continuing resurgence in pertussis, efforts should focus on maximizing Tdap uptake among pregnant women.

Keywords: Tdap; infant; maternal immunization; pertussis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest: None of the authors have conflicts of interest to disclose.

Figures

Figure 1a
Figure 1a. Timing of Tdap Doses Classified as During Pregnancy
The white bars represent Tdap doses received by control-associated mothers during pregnancy, and the gray bars represent Tdap doses received by case-associated mothers during pregnancy. *2 cases were missing gestational age so the exact week of Tdap administration could not be calculated; based on date of birth and Tdap date, both cases were included in the second trimester of pregnancy in the analysis models.
Figure 1b
Figure 1b. Timing of Tdap Doses Classified as Before Pregnancy
The white bars represent Tdap doses received by control-associated mothers before pregnancy, and the gray bars represent Tdap doses received by case-associated mothers before pregnancy. *1 case missing gestational age so the exact month of Tdap administration before pregnancy could not be calculated; based on date of birth and Tdap date, this case was included in the ≤2 year group in the analysis models.
Figure 1c
Figure 1c. Timing of Tdap Doses Classified as Post-partum
The white bars represent Tdap doses received by control-associated mothers during the post-partum period, and the gray bars represent Tdap doses received by case-associated mothers during the post-partum period.
See this image and copyright information in PMC

References

    1. Clark T. Changing pertussis epidemiology: everything old is new again. The Journal of infectious diseases. 2014;209(7):978–81. - PubMed
    1. Bozio C, Skoff TH, Pondo T, Liang J. Epidemiology and Trends of Pertussis among Infants – United States, 2000–2015; 2017 Annual Epidemic Intelligence Service Conference; Atlanta, GA. April 24–27, 2017.
    1. Skoff TH, Kenyon C, Cocoros N, et al. Sources of Infant Pertussis Infection in the United States. Pediatrics. 2015;136(4):635–41. - PubMed
    1. Wendelboe AM, Njamkepo E, Bourillon A, et al. Transmission of Bordetella pertussis to young infants. Pediatr Infect Dis J. 2007:26. - PubMed
    1. Kretsinger K, Broder KR, Cortese MM, et al. Preventing tetanus, diphtheria, and pertussis among adults: use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis vaccine recommendations of the Advisory Committee on Immunization Practices (ACIP) and recommendation of ACIP, supported by the Healthcare Infection Control Practices Advisory Committee (HICPAC), for use of Tdap among health-care personnel. MMWR Recomm Rep. 2006;55(RR-17):1–37. - PubMed

Publication types

MeSH terms

Substances